Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer - Wikidata - wikimedia - TriplyDB

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

http://www.wikidata.org/entity/Q36184256

about

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer c-Met as a Target for Personalized Therapy MET deregulation in breast cancer The clinical and functional significance of c-Met in breast cancer: a review Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma.Role of HGF/MET axis in resistance of lung cancer to contemporary management.Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.Exogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell Lines Novel agents that downregulate EGFR, HER2, and HER3 in parallel MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer MET/HGF pathway activation as a paradigm of resistance to targeted therapies.HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer.Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer.Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.Metastatic breast cancer: The Odyssey of personalization.Development of antibody-based c-Met inhibitors for targeted cancer therapy.Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling.Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer.Identifying the challenges of biomarkers that predict response to HER2-directed therapies.Met, IGF1R, and other new targets in upper GI malignancies.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.Genes and functions from breast cancer signatures.

P2860

Q26772969-D84179C9-6B73-46C8-B28A-DF6CAED2D908 Q26775483-1EA8B3B5-450A-473D-933C-7C6B409D81F5 Q26781054-7EEFD8E7-3ACA-4FC7-B4F4-609B8DD22DC3 Q28081415-DA4F0C20-3BEC-4BB6-BDAB-4CCC87AA0321 Q28087523-7FDDC6B4-6801-4ECE-A0CC-70A149696961 Q33555302-0EB39850-52CE-4386-A732-BDE1DD72B52F Q33601653-7DB061EC-9DC3-43AB-B55C-FDBC47DBCAD8 Q33822560-4154DEBA-86CE-409F-AD5E-98FEE263E144 Q34704781-1A6287AB-6130-4AA1-B6BC-C931DFC8D860 Q35017808-A6EC3A12-5181-46B4-9297-9DD77891C333 Q35200337-68D790AC-5315-43FD-9E7C-72E7758CA42A Q35222611-18902706-FB10-44F8-8F5B-22B0E7A9404C Q35818728-720B5162-358D-441C-A19C-EDAE85EEC05E Q35833034-A28B22E9-8AFA-4A14-8B61-475E788A90C6 Q36117367-C7708181-BE9A-4468-8E61-C21CAC12E180 Q36440214-E23BFD68-D5A4-4FE4-9972-38A3F15D37EB Q36782629-A9D67DD3-8B19-4B71-AF49-77CF46D1C68A Q36907273-C90B3E97-C152-42F2-945D-739CC0D715C8 Q37597850-20A9053D-0FB8-44BC-92FA-33459F6B94EA Q37632192-BB4E922A-7976-47D9-89BD-7714E63D0E09 Q37694805-248DE91E-1584-4DA8-97B4-922FBC5C1276 Q38089600-BFC508A0-736B-432A-BE96-BADD4D7BA3AD Q38214802-0409F4AC-A2D3-43B4-B48A-344D43001C5E Q38476204-84788B52-5839-4FB0-9987-88B0B36B8666 Q38591976-F81307F2-CB12-4A94-8E8D-E86516C4B1D4 Q38786102-B437B190-3BA5-444C-893D-DDB1B1F87976 Q38801405-BE0CA161-D1FC-4756-8DFD-FD8EC2D2F6B8 Q38901163-B06D6CDF-FB93-4A14-ACB6-2A15F03DDBA1 Q38912279-F6E4626B-FB12-4633-B4CD-007F711D1911 Q38941704-DFB59F09-E401-4D9B-B4E4-23CE096AEE6F Q38948901-007B295B-E08D-4429-8978-50B18517D037 Q39028181-7CB8BC26-5192-4DF1-B847-35C060F00EFC Q39327784-D1CDA085-E529-4F2B-BAA9-E760817880B4 Q41708988-524E64AB-28B3-4212-8EF7-B38F4C356A8C Q42289084-569BD795-DEA4-4119-9B15-9E403CDFF9C6 Q43628088-44646766-24C2-43C3-AE75-A0304075624D Q47967299-6CE41F22-6598-4434-A354-408B23775D86 Q49544395-33DADBC6-ED75-43B6-B0C9-A5D7EF664A3F Q50985091-1E6410CB-2AD4-46FA-854C-741C8572D83E Q52560707-A20E1EDD-6592-474E-A1B0-BD5E5B1BB36F

P2860

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

http://www.wikidata.org/entity/Q36184256

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Increased MET and HGF gene cop ...... itive metastatic breast cancer

@ast

Increased MET and HGF gene cop ...... itive metastatic breast cancer

@en

type

label

Increased MET and HGF gene cop ...... itive metastatic breast cancer

@ast

Increased MET and HGF gene cop ...... itive metastatic breast cancer

@en

prefLabel

Increased MET and HGF gene cop ...... itive metastatic breast cancer

@ast

Increased MET and HGF gene cop ...... itive metastatic breast cancer

@en

P1433

Q36184256-F9668E7E-3DC5-47C6-879B-A373304735BF

P1476

Q36184256-FC603891-3563-440F-8E25-A0035B53B213

P2093

Q36184256-106AF769-4FEE-4809-87DC-DC7306152930

Q36184256-1C7EA2AF-FD19-41FB-881C-4F5E2AF84CDB

Q36184256-3C875BF9-D048-4FAB-927B-CF71AD6A4AC2

Q36184256-40D2248E-2F2D-4774-B48F-08268D0DC73C

Q36184256-52682117-0AE8-49FA-AF30-63826C72F0CA

Q36184256-64C47FAA-EE8E-453A-A836-5D6BAF5AAA10

Q36184256-80E0EB6A-5B62-4CD8-9970-6E636F7F0EBC

Q36184256-8B306B4E-289F-4CBB-9374-5EDFEF0BEFA7

Q36184256-98065FF9-875B-4938-9C62-A841D6219267

Q36184256-A2F91D44-F765-4EBD-83D1-A14D1724DB88

P2860

Q36184256-0C6524A7-82C0-4573-BBEA-EEC3E8BF4954

Q36184256-238578D1-8F7B-4A9C-AD80-DCC40CA9A9F0

Q36184256-27587E46-2722-40EC-A39E-AD55389E4A11

Q36184256-2DE924C2-98A1-4C8B-83A0-29AFCE1B07D6

Q36184256-2FAF3201-AB22-431F-8C8D-19E4BD911A21

Q36184256-30DA5828-4B8C-45F6-B634-D138FC40C91B

Q36184256-30DB6CB4-67FA-4BFA-A240-0DAA0C0286E3

Q36184256-4437FC8D-334E-4817-89FC-7506C6C78D35

Q36184256-484BFE11-8D65-4E66-B08C-49B2C707395D

Q36184256-58904D63-AEF8-4A74-8C6B-C27ECEA9BE19

P2888

Q36184256-503011A4-EB5C-44E7-9519-9B7E2F2A22ED

P304

Q36184256-E5306973-37D8-43D8-8E05-9B70D9350B66

P31

Q36184256-96069B94-3257-4058-9550-B667BD2EE0E6

P356

Q36184256-68B41011-1BD0-4914-A9FF-44A6FBC28D43

P407

Q36184256-3EE7ED8A-3349-449A-B22B-DD70E8704039

P433

Q36184256-9E3A99CF-1EFB-4885-BA63-7650AA85D59C

P478

Q36184256-2EFB7A0C-CF41-495D-B1E6-5A3C2A1FEA14

P50

Q36184256-2D19DAD6-7433-4320-9292-AB0262081DBC

Q36184256-308A65AD-4D65-4251-95FC-336090ED2898

Q36184256-46D8E3E6-E68F-4781-AACE-19A44D9B5467

P577

Q36184256-352C2BDF-4003-4C2E-9C80-41A478343598

P5875

Q36184256-CDB99694-81A8-46B1-B5BC-882E58F63F10

P698

Q36184256-C08C893B-EDF2-404B-A821-F07496D71426

P932

Q36184256-5DB692FC-DE78-46D8-9DCC-0BEDA23CC944

P356

P1433

British Journal of Cancer

P1476

Increased MET and HGF gene cop ...... itive metastatic breast cancer

@en

P2093

A D Mendoza

http://www.w3.org/2001/XMLSchema#string

A Tempińska-Szałach

http://www.w3.org/2001/XMLSchema#string

B Czartoryska-Arłukowicz

http://www.w3.org/2001/XMLSchema#string

B Szostakiewicz

http://www.w3.org/2001/XMLSchema#string

D Zuziak

http://www.w3.org/2001/XMLSchema#string

E Rossi

http://www.w3.org/2001/XMLSchema#string

G Minuti

http://www.w3.org/2001/XMLSchema#string

J Jassem

http://www.w3.org/2001/XMLSchema#string

J Zok

http://www.w3.org/2001/XMLSchema#string

L Landi

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

Humanization of an anti-p185HER2 antibody for human cancer therapy

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Nonparametric Estimation from Incomplete Observations

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

P2888

P304

793-799

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2012.335

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Federico Cappuzzo

Terence J O'Brien

Alessandra Fabi

P577

2012-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230591954

http://www.w3.org/2001/XMLSchema#string

P698

22850551

http://www.w3.org/2001/XMLSchema#string

P932

3425981

http://www.w3.org/2001/XMLSchema#string